phrykt

Aligos Therapeutics, Inc. (ALGS): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of ALGS were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Aligos Therapeutics

From the latest filings

Overall: more buying than selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ALGS

31 funds and institutions reported ALGS shares worth $13.2M at the end of Q2 2026. The largest holder is Deep Track Capital, LP with $2.6M.

10 largest owners, by value

Deep Track Capital, LP$2.6M
Alyeska Investment Group, L.P.$2.4M
Sio Capital Management, LLC$1.9M
Marshall Wace, LLP$1.4M
Woodline Partners LP$1M
Vanguard Capital Management LLC$1M
Baker Bros. Advisors LP$479K
Hhlr Advisors, Ltd.$440K
D. E. Shaw & Co., Inc.$383K
UBS Group AG$346K

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Deep Track Capital, LP444,110–$2.6MNo change
Alyeska Investment Group, L.P.412,000–$2.4MNo change
Sio Capital Management, LLC327,237–$1.9MNo change
Marshall Wace, LLP246,579–$1.4M-8%
Woodline Partners LP177,362–$1MNo change
Vanguard Capital Management LLC175,543–$1M-2%
Baker Bros. Advisors LP83,055–$479KNo change
Hhlr Advisors, Ltd.76,247–$440KNo change
D. E. Shaw & Co., Inc.66,463–$383K+505%
UBS Group AG59,986–$346K+62%
Geode Capital Management, LLC47,173–$272K-6%
Jane Street Group, LLC32,402–$187KNew
BlackRock, Inc.30,292–$175K+132%
Vanguard Fiduciary Trust Co28,612–$165K+1%
Dimensional Fund Advisors LP21,044–$121KNew
Verition Fund Management LLC18,887–$109KNo change
Trexquant Investment LP12,339–$71.2KNew
Renaissance Technologies LLC10,800–$62.3K-89%
Rockefeller Capital Management L.P.10,000–$57.7KNo change
Federation des caisses Desjardins du Quebec4,650–$26.8K+389%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No ALGS insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ALGS short interest

677,218 ALGS shares are sold short. Over the last 12 reports the number of shares short went up 27%.

As of Oct 30, 2026, 677,218 ALGS shares were sold short, down 4.3% from the report before. At the average daily volume of 32,604 shares, buying them all back would take about 20.8 trading days (days to cover).

Shares short

677,218May 15Oct 30736,843

Days to cover

20.8May 15Oct 3024.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026677,218–-4%32,60420.8
Oct 15, 2026707,471–-0%32,54921.7
Sep 30, 2026708,744–+2%49,39214.3
Sep 15, 2026697,683–+8%45,44915.3
Aug 31, 2026648,568–+14%68,8919.4
Aug 14, 2026568,056–-6%209,3822.7
Jul 31, 2026606,525–+16%94,9456.4
Jul 15, 2026521,416–-4%514,1951.0
Jun 30, 2026543,337–-11%68,4427.9
Jun 15, 2026611,712–+6%99,8376.1
May 29, 2026576,909–+8%121,4044.8
May 15, 2026535,177–+9%155,2193.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Aligos Therapeutics company events

Aligos Therapeutics filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 6, 2026.

  1. Nov 6, 2026ResultsReleased financial results. Filing
  2. Sep 15, 2026AgreementAligos Therapeutics, Inc. entered into the First Amendment to Lease with Britannia Biotech Gateway Limited Partnership, to amend the Lease, dated as of June 21, 2018, by and between the Landlord and the Company (as amended, the “Lease”), relating to office space located at One Corporate Drive, 2 nd… Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. Jun 26, 2026LeadershipAligos Therapeutics, Inc. held its Annual Meeting of Stockholders. Filing
  5. May 7, 2026ResultsReleased financial results. Filing
  6. Apr 21, 2026AgreementAligos Therapeutics, Inc. entered into a License Agreement with Xiamen Amoytop Biotech Co., Ltd., pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and… Filing
  7. Apr 14, 2026AnnouncementAligos Therapeutics, Inc. issued a press release announcing the first interim analysis results of the Phase 2 B-SUPREME study of pevifoscorvir sodium in participants with chronic hepatitis B virus infection for the Part 2a (HBeAg- cohort) where the independent Data Safety Monitoring Review Board… Filing
  8. Mar 5, 2026ResultsReleased financial results. Filing
  9. Feb 4, 2026LeadershipThe Board of Directors of Aligos Therapeutics, Inc. appointed Nikhil Aneja as the Company’s Principal Accounting Officer, effective immediately. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Aligos Therapeutics financials

Famous investors that hold ALGS

2 of the 50 well-known investors we track reported holding ALGS in their latest 13F filing. The largest position is Jim Simons's, worth $85K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202615,100$85K0.0%+40%
Ken Griffin · Citadel AdvisorsQ3 202611,539$65K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ALGS in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Alyeska Investment Group, L.P.13G/A5.6%
Nov 16, 2026Alyeska Investment Group, L.P.13G/A5.6%
Nov 13, 2026Parkman Healthcare Partners LLC13G5.2%
Nov 13, 2026Parkman Healthcare Partners LLC13G5.2%

Questions about Aligos Therapeutics, Inc. (ALGS) stock

Who owns the most ALGS stock?

The largest reported owner of Aligos Therapeutics, Inc. (ALGS) is Deep Track Capital, LP. In total, 31 funds and institutions reported holding ALGS at the end of Q2 2026. See the largest owners.

Are ALGS insiders buying or selling?

No ALGS insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in ALGS?

As of Oct 30, 2026, 677,218 ALGS shares were sold short, down 4.3% from the report before. At the average daily volume of 32,604 shares, buying them all back would take about 20.8 trading days (days to cover). See the history.

Which famous investors hold ALGS?

2 of the 50 well-known investors we track reported ALGS in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $85K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.